Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy Study Description

Last updated: April 27, 2022
Sponsor: University Medical Center Ho Chi Minh City (UMC)
Overall Status: Active - Recruiting

Phase

N/A

Condition

Gastric Cancer

Digestive System Neoplasms

Stomach Cancer

Treatment

N/A

Clinical Study ID

NCT05029869
81/GCN-HDDD 2021
  • Ages > 18
  • All Genders

Study Summary

This study aims to evaluate the use of Next Generation Sequencing (NGS) to detect circulating tumor DNA in gastric cancer patients after gastrectomy

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male or Female patients aged 18 years and older
  2. Histologically proven primary gastric adenocarcinoma before surgery
  3. Clinical stage is locally advanced cT2-4a any N and M0
  4. In initial evaluation, patient can undergo radical gastrectomy and lymphadenectomy
  5. No preoperative therapy, including chemotherapy and radiotherapy
  6. No known cancer diagnosis within last five years
  7. Signed informed consent

Exclusion

Exclusion Criteria:

  1. Gastrectomy cannot be achieved during operation due to metastasis
  2. Patient fails to follow-up and provide postoperative samples

Study Design

Total Participants: 100
Study Start date:
October 04, 2021
Estimated Completion Date:
October 01, 2024

Study Description

Gastric cancer is the fourth most common cancer in Vietnam with high mortality rate. Patients at early stages undergo radical gastrectomy with curative intent, but the remaining tumor cells, termed as minimal residual disease (MRD), can later cause relapse. Conventional methods to monitor MRD such as imaging and blood tests for biomarkers such as CEA are not sensitive and specific enough. ctDNA has recently emerged as a promising noninvasive marker with high accuracy to monitor MRD and detect relapse in many cancers such as breast and colorectal cancers. However, its application in gastric cancer has not been extensively evaluated. Therefore, this study aims to use advanced NGS technologies to detect ctDNA in liquid biopsy as a biomarker to monitor MRD after radical gastrectomy.

Connect with a study center

  • University Medical Center Ho Chi Minh City

    Ho Chi Minh City, 700000
    Vietnam

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.